Tapi Nl Bv, based in Israel, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is NINTEDANIB ESYLATE, with a corresponding US DMF Number 37872.
Remarkably, this DMF maintains an Active status since its submission on December 29, 2022, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of January 19, 2023, and payment made on December 20, 2022, indicating their dedication to facilitating drug approvals, Categorized as Type II